Fallout over two recent studies highlights the potential power of social media to shape science, and the shifting dynamics between researchers and the autistic community.

The hormone is no better than placebo at boosting social behavior in autistic children, according to a new study, but it may still benefit a subset of people with the condition.

After imposing a pause in November 2020, the U.S. Food and Drug Administration has cleared the way for a clinical trial of a gene therapy for Angelman syndrome.

A drug that helps promote gene expression reduces repetitive behaviors and improves memory and sociability in a mouse model of autism.

The stubborn lack of treatments for fragile X syndrome — a leading cause of inherited intellectual disability and autism — is spurring researchers to revise clinical trial techniques and revisit old drug candidates.

For 40 years, the preponderance of autism research has focused on understanding the causes and characteristics of the condition rather than testing assessments or interventions in community settings.

Octopuses can solve some of the same problems as people but do so in unusual ways.

The finding that MDMA and an experimental serotonin agonist increase sociability across six different model mice suggests that disparate autism-linked mutations converge on the same underlying pathways.

Disparities in state services for autism are driving families to relocate. But not everyone can afford to move, and others find that their new home also has faults.

The double empathy theory challenges the idea that social difficulties are specific to autism and suggests that problems arise from a mismatch in perspective between autistic and non-autistic people.